SCHEMBL5378908

SCHEMBL5378908

O=C(O)c1cc(O)cc(Oc2ccccc2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.65
SRD5A2 P31213 3/20 0.55
CA12 O43570 2/20 0.54
CA1 P00915 2/20 0.54
CA2 P00918 2/20 0.54
CA9 Q16790 2/20 0.54
CA7 P43166 1/20 0.54
CA14 Q9ULX7 1/20 0.54
TTR P02766 1/20 0.53
GPBAR1 Q8TDU6 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
LTA4H P09960 1/20 0.50
NR1H2 P55055 1/20 0.50
BAX Q07812 1/20 0.50
HDAC8 Q9BY41 1/20 0.49
MCL1 Q07820 1/20 0.48
NR4A2 P43354 1/20 0.47
PARP10 Q53GL7 1/20 0.47
CA6 P23280 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5374451 0.89 PARP10 (0.56) AKR1C3SRD5A2CA12CA1CA2
SCHEMBL5747830 0.88 AKR1C3 (0.74) AKR1C3SRD5A2TTRMEN1KMT2A
SCHEMBL1768785 0.88 AKR1C3 (0.74) AKR1C3SRD5A2TTRMEN1KMT2A
SCHEMBL710275 0.83 CA12 (0.59) AKR1C3CA12CA1CA2CA9
SCHEMBL11579816 0.82 LTA4H (0.65) AKR1C3CA1CA2MEN1KMT2A
SCHEMBL5712250 0.82 LTA4H (0.65) AKR1C3CA1CA2MEN1KMT2A
SCHEMBL851606 0.82 PARP15 (0.55) AKR1C3SRD5A2CA12CA1CA2
SCHEMBL12604615 0.82 SMN1; SMN2 (0.54) AKR1C3MEN1KMT2ALTA4HNR1H2
SCHEMBL14811923 0.80 AKR1C3 (0.62) AKR1C3SRD5A2CA1CA2TTR
SCHEMBL28363894 0.80 HCAR1 (0.69) AKR1C3CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7196214-B2 Process for arylamine production XEROX CORPORATION (US) 2007-03-27 US claimed
US-20060111582-A1 Process for arylamine production XEROX CORPORATION (US) 2006-05-25 US claimed
US-9149019-B2 Method of eliminating cat urine odor JMR, LC (US) 2015-10-06 US disclosed
US-20130323194-A1 METHOD OF ELIMINATING CAT URINE ODOR CO2 TECHNOLOGIES, INC. (US) 2013-12-05 US disclosed
EP-2459554-B1 SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS CADILA HEALTHCARE LTD (IN) 2013-09-18 EP disclosed
WO-2011013141-A2 SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS CADILA HEALTHCARE LIMITED (IN) 2011-02-03 WO disclosed
US-7196214-B2 Process for arylamine production XEROX CORPORATION (US) 2007-03-27 US disclosed
US-20070066170-A1 CO2 GENERATING ABSORBENT PADS CO2 TECHNOLOGIES, INC. (US) 2007-03-22 US disclosed
US-7189666-B2 CO2 generating absorbent pads CO2 TECHNOLOGIES (US) 2007-03-13 US disclosed
US-7160939-B2 Preservatives; mixture of carbon dioxide in polymer matrix; mixture containing citric acid, calcium carbonate and low density polyethylene CO2 TECHNOLOGIES, INC. 2007-01-09 US disclosed
US-20060111582-A1 Process for arylamine production XEROX CORPORATION (US) 2006-05-25 US disclosed
WO-2005005520-A2 ACTIVE MASTERBATCH FOR PRODUCTION OF CO2 GENERATING MASTERBATCH CO2 TECHNOLOGIES, INC. (US) 2005-01-20 WO disclosed
US-20050001204-A1 Active masterbatch for production of CO2 generating masterbatch CO2 TECHNOLOGIES, INC. (US) 2005-01-06 US disclosed
WO-2004110876-A2 CO2 GENERATING ABSORBENT PADS CO2 TECHNOLOGIES, INC. (US) 2004-12-23 WO disclosed
US-20040247750-A1 CO2 generating absorbent pads CO2 TECHNOLOGIES, INC. 2004-12-09 US disclosed
US-6797235-B2 Device and methods for modifying an atmosphere CO2 TECHNOLOGIES, INC. 2004-09-28 US disclosed
WO-2004022112-A1 DEVICE AND METHODS FOR MODIFYING AN ATMOSPHERE CO2 TECHNOLOGIES, INC. (US) 2004-03-18 WO disclosed
US-20040047760-A1 Device and methods for modifying an atmosphere LONGER SHELF LIFE, LLC 2004-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111582-A1 Process for arylamine production AOC2, UFM1, TYR AKR1C3 2668/4885SRD5A2 2466/4885CA12 4463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.